TPD

(redirected from Therapeutic Products Directorate)
Also found in: Acronyms, Wikipedia.

TPD

Abbreviation for:
temporary partial disability
Therapeutic Products Directorate (Canada)
threatened preterm delivery
tidal peritoneal dialysis
Training Programme Director, see there 
tropical pancreatic diabetes
two-point discrimination
Mentioned in ?
References in periodicals archive ?
InSite Vision obtained regulatory approval of AzaSite from the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis (pink eye) in adults and children one year and older.
21 January 2011 - Canada-based specialty pharmaceutical company Labopharm Inc (TSE: DDS) announced yesterday that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO (trazodone hydrochloride Extended Release Tablets), a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder (MDD) in adults.
to) said on Thursday that OLEPTRO (trazodone hydrochloride Extended Release Tablets) has been approved by Health Canada's Therapeutic Products Directorate (TPD).
Amex: ISR) announced today that Health Canada's Therapeutic Products Directorate has approved Proxcelan Cs-131 brachytherapy seeds for sale throughout Canada.
InSite Vision Incorporated (AMEX:ISV) today announced that the Therapeutic Products Directorate (TPD) of Health Canada has approved the company's new drug submission (NDS) for AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis (pink eye) in adults and children one year and older.
TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it has received an expanded indication for once-daily Ralivia[TM] - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada.
Food and Drug Administration, Canadian Therapeutic Products Directorate and European regulatory approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, infringement and alleged infringement of Biovail's intellectual property rights and those of others, the regulatory environment, tax rate assumptions, the outcome of legal proceedings and settlements thereto, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the U.

Full browser ?